BLOG

HCP

DM199 shows promise in phase 2 trial for treating preeclampsia

DM199 (rinvecalinase alfa; DiaMedica Therapeutics) has shown positive results for treating preeclampsia in part 1a of a phase 2 clinical trial, according to DiaMedica Therapeutics Inc.1